Pharmaceuticals News and Research

RSS

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

27 Oct 2009

Unifill ready-to-fill safety syringes to hit markets soon

Unilife Medical Solutions Limited today announced it has commenced the filing of international trademarks for Unifill™, which will become the market brand for its portfolio of ready-to-fill safety syringes.

27 Oct 2009

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.

27 Oct 2009

Positive results from Phase II clinical trial of INT-747 announced

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).

27 Oct 2009

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its third purchase order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry and Information Technology for the national stockpiling plan.

27 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

New Trace Express Viewer software from CDC Software

CDC Software Corporation, a global provider of enterprise software applications and services, today announced the availability of Trace Express Viewer, a new solution for its Ross ERP Lot Trace application that enables easier use, faster access and immediate forward and backward trace functionality to identify suspect materials and assist in the disposition of finished goods in the event of a product recall - key functionalities for product safety and compliance.

27 Oct 2009

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and KOKEN Co., Ltd., a leading atelocollagen company, announced today that Alnylam has granted KOKEN a non-exclusive worldwide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family.

27 Oct 2009

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Life Technologies Corporation (NASDAQ:LIFE) today announced results for its third quarter ended September 30, 2009. Non-GAAP revenue for the third quarter was $805 million, an increase of 3 percent over third quarter revenue of $784 million in 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 27 Oct 2009

Hospira announces fiscal 2009 third-quarter results

Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today reported results for the third quarter ended Sept. 30, 2009. Net sales for the quarter were $1.0 billion, and adjusted diluted earnings per share were $0.90.

27 Oct 2009

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into an agreement allowing Eli Lilly and Company (NYSE: LLY) select access to research from its osteoarthritis genomic biomarker program

27 Oct 2009

BioMarin Pharmaceutical acquires Huxley Pharmaceuticals

Rodman & Renshaw Capital Group, Inc. announced today that its affiliate, Aceras BioMedical LLC (Aceras), has sold Huxley Pharmaceuticals Inc. (Huxley), a portfolio company, to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Huxley was established by Aceras in August 2008 with a focus on developing therapeutic products for rare diseases of the nervous system.

27 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

CCPM coalition members urge Congress to fix or drop the current biogenerics provision

The Coalition for a Competitive Pharmaceutical Market (CCPM), its allied organizations, representing several hundred million Americans, join experts from the medical and research communities, economists and thought leaders appealing to Congress to fix the excessive 12-year market exclusivity and ever-greening provisions for biologics or drop it altogether.

27 Oct 2009

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Fero Industries, Inc. is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

27 Oct 2009

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009.

27 Oct 2009

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

BMC surgeons use new EsophyX TIF for treatment of acid reflux or GERD

Boston Medical Center (BMC) surgeons are now offering patients an incisionless alternative to laparoscopic and traditional surgery for treatment of acid reflux or GERD.

27 Oct 2009

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.

27 Oct 2009

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company’s TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

27 Oct 2009

Pharmaceuticals News and Research

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Unifill ready-to-fill safety syringes to hit markets soon

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Positive results from Phase II clinical trial of INT-747 announced

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

New Trace Express Viewer software from CDC Software

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Hospira announces fiscal 2009 third-quarter results

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

BioMarin Pharmaceutical acquires Huxley Pharmaceuticals

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

CCPM coalition members urge Congress to fix or drop the current biogenerics provision

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

BMC surgeons use new EsophyX TIF for treatment of acid reflux or GERD

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring